Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms
-
By
-
Yudi Zhang
-
Wei Wang
-
Qiaoli Li
-
Li Ye
-
Xinping Zhou
-
Lingxu Jiang
-
Liya Ma
-
Yingwan Luo
-
Hongyan Tong
-
May 29, 2026
-
Clinical Scorecard: Influence of Clonal Structure and Potential Biallelic Inactivation of TET2 Mutations in Myelodysplastic Syndromes
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | TET2 mutations, clonal hierarchy, biallelic inactivation |
| Target Population | |
| Care Setting | |
Key Highlights
- TET2 mutations are frequent in MDS.
- Ancestral TET2 mutations are associated with younger age.
- Secondary TET2 mutations correlate with shorter survival.
- Biallelic TET2 inactivation defined by cumulative VAF ≥ 50%.
- Clonal hierarchy retains prognostic significance.
Guideline-Based Recommendations
Diagnosis
- MDS diagnosis based on WHO 2016 criteria.
Management
- Consider hypomethylating agents for treatment.
Monitoring & Follow-up
- Monitor for leukemic transformation.
Risks
- Secondary TET2 mutations associated with inferior overall survival.
Patient & Prescribing Data
Response to HMAs may differ based on TET2 mutation status.
Clinical Best Practices
- Evaluate clonal hierarchy for prognostic assessment.
- Monitor mutation burden in MDS patients.
Related Resources & Content
